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Abstract
Microalbuminuria is a marker of early diabetic nephropathy and 
cardiovascular risk.  Immunoassays for urinary albumin can 
underestimate the amount of intact albumin present in urine. The
purpose of this study was to evaluate a new urinary albumin assay 
that employs size exclusion HPLC with UV detection to quantify 
urinary albumin.  We determined the limit of detection (LOD), 
linearity, imprecision, comparison to an immunoturbidimetric 
assay (ITA), and pediatric and adult reference intervals on random 
urine collections. All subjects for reference interval studies were 
apparently healthy and none were taking prescription medications
other than oral contraceptives. Boys and girls ranged from 7 to 17 
years of age and 20 boys and 20 girls from each of these years of life 
were included.  The LOD was 3.4 mg/L.  The assay was linear from
4 to 240 mg/L.  Within run imprecision was 4.9, 0.9, and 0.7% at
16, 89, and 206 mg/L, respectively.  Total imprecision was 8.4, 3.1, 
and 2.9% at 16, 89, and 206 mg/L, respectively. Passing-Bablok 
analysis of HPLC versus ITA for 101 samples with 
albumin/creatinine ratios by ITA of 20 to 200 mg/g showed a 
positive proportional bias with a slope of 1.77, an intercept of 2.2 
and r = 0.83.  For 103 samples with albumin/creatinine ratios by
ITA from 200 to 1000 mg/g, the slope was 1.33, the intercept was 20 
and r = 0.87.  Non-parametric reference intervals for both the ITA 
and HPLC methods are shown in the Table 2.  The HPLC assay for 
total urinary albumin shows acceptable performance and 
quantifies albumin species not detected by immunoassay.  Our 
studies of apparently healthy children and adults suggest the need 
for separate male and female and pediatric and adult reference 
intervals.  Further outcome studies are necessary to determine how 
to best interpret urinary albumin measurements made by HPLC.
Introduction
Microalbuminuria (MA) is defined as the excretion of albumin in 
urine at levels of 20-200 ug/min or 30-300 mg/24hr for timed 
collections and 30-300 mg/g creatinine for random or spot urine 
samples.  In type 1 and type 2 diabetes mellitus, MA is considered 
the earliest marker of diabetic nephropathy.  Type 1 diabetics have 
been shown to develop nephropathy in >30% of cases.  
Approximately 25% of patients with type 2 diabetes mellitus have
been shown to develop nephropathy 5-10 years after diagnosis.  
Diabetic nephropathy is the most common causes of end-stage renal 
disease in the US and Europe.  The ability to detect MA early is
clinically important because of the potential to initiate use of anti-
angiotensin therapy in order to stop or slow the progression of 
diabetic nephropathy.  In addition, MA has been shown to be a 
marker for increased risk of cardiovascular morbidity and 
mortality in both diabetic and non-diabetic patients.1,2,3
The ability to measure accurately and precisely the low 
concentrations of albumin in urine associated with MA has been 
facilitated by the development of automated immunoassay methods.
Previously we have studied the performance of some of these 
commercially available assays.  A series of recent studies have 
shown that current immunoassay methods may underestimate the 
amount of intact albumin in urine from diabetic subjects, especially 
at excretion rates less than 100 ug/min.4-8 These studies have 
compared various immunoassay methods to a new HPLC assay that 
uses size exclusion chromatography.  This method has recently 
received FDA clearance for the measurement of albumin in urine. 
The purpose of our study was to evaluate the analytic performance 
of this new assay and compare it to a conventional microalbumin 
immunoassay in normal and diabetic subjects.   The need for robust 
reference intervals for both children and adults for this assay was a 
primary focus for this study.
Methods
 Wako Microalbumin B ITA assay (Wako Diagnostics, 
Richmond, VA) run on a Roche Modular P (Roche Diagnostics, 
Indianapolis, IN).  This was used as  the comparison method for 
our studies.
 Accumin direct total intact albumin by HPLC kit (AusAm 
Biotechnologies Inc., New York, NY) run on an Agilent/HP 1100 
(Agilent Technologies, Los Angeles, CA) instrument.
 Two immunonephelometric assays (INA) for albumin  were 
used.  One on the BN II nephelometer using the manufacturer’s 
reagent (Dade Behring, Deerfield, IL), and the other on the 
IMMAGE nephelometer using manufacturer’s reagents 
(Beckman Coulter, Brea, CA).
 An immunochemiluminometric assay (ICMA) for albumin run 
on an IMMULITE 2000 instrument (Diagnostic Products 
Corporation, Los Angeles, CA) using manufacturer’s reagent.
 Urinary creatinine testing by the Jaffe method on a Roche 
Modular P instrument using the manufacturer’s reagent (Roche 
Diagnostics, Indianapolis, IN).
Procedures
The (LOD) was determined by assaying 10 replicate injections of 
the mobile phase buffer and 3 replicate injections of the low 
calibrator provided in the Accumin kit.  The maximum 
amplitude from the buffer injections indicating the background 
noise level for the assay was compared to the average amplitude 
of the low calibrator, which had a concentration of 9.41mg/L.  
From the relationship of amplitude to albumin, a concentration 
of albumin equivalent to five times the background noise was 
determined to be the LOD.  Linearity studies were performed 
using dilute urine from a healthy male volunteer (low pool) and 
supplementing with human serum albumin (Sigma, St. Louis, 
MO) to create a high pool.  The high pool was diluted with the 
low pool to produce the following final concentrations of the high 
pool: 0%, 2.5%, 5%, 10%, 25%, 50%, 75% and 100%.  These 
samples were analyzed in duplicate. Materials for imprecision 
testing were prepared by taking a dilute urine sample from a 
healthy volunteer and supplementing it with human serum 
albumin to produce three concentrations of albumin.  Each 
imprecision pool was aliquotted and frozen at -70 0C until it was 
analyzed.  Sufficient aliquots were prepared to perform two runs
in duplicate per day for 10 days, for a total of 40 replicates per 
pool.
Method comparison samples with moderate albumin creatinine 
ratios (ACR) defined as 20 to 200 mg/g (n=101), and high ACR 
samples defined as 200 to 1000 mg/g (n=103) were retrieved from 
our patient sample frozen storage at -20 0C.  They were then de-
identified, and placed at   -70 0C until time of testing.  Before 
analyzing for albumin by HPLC, these samples were thawed, 
vortexed gently to mix and centrifuged at 3000g for 10 min.  This 
albumin result was used to calculate the ACR using the original 
creatinine result.  Adult reference samples were collected from 
apparently healthy volunteer subjects working at our company.  
Potential reference subjects were excluded for the following 
reasons: diabetes mellitus, hypertension, prescription 
medications except oral contraceptives, urinary tract infection in 
the last month, and females subjects who were menstruating.  
Our reference subjects included 80 males and 80 females, and 
ranged in age from 19 to 66 years.  The samples were first or 
second morning void samples.  Aliquots were frozen at -70 0C 
until time of analysis.  Since our reference study subjects live at 
moderate altitude (1370 m) we arranged for reference samples to 
be collected from healthy volunteers living at sea level to account 
for any effect of altitude.  The sea level samples were shipped 
frozen to our facility from their collection point.  These samples 
were chiefly from young adults and included 66 females and 54 
males with an age range from 18 to 26 years with one subject of 
46 years. They were stored at -70 0C until time of testing.  Our 
pediatric reference samples were random collections from 
healthy children who were on no prescription medications and
Fig. 3. Comparison of HPLC and ITA in normal subjects.  The solid line indicates 
Passing-Bablok regression line and the dashed line indicates x = y.  In panel A, 
results form 216 pediatric female samples are shown.  Passing-Bablok regression 
analysis gave a slope of 1.78 (1.67-1.92), an intercept of 20.4 (18.4-22.6), and          
r = 0.956.  In panel B, results from 216 pediatric male samples are shown. 
Passing-Bablok regression analysis gave a slope of 1.90 (1.70-2.14), an intercept of 
18.4 (15.9-20.8), and r = 0.872. In panel C, results from 143 adult female samples 
are shown.  Passing-Bablok regression analysis gave a slope of 1.73 (1.48-2.07), an 
intercept of 10.4 (7.4-12.1), and r = 0.625.  In panel D, results from 132 adult male 
samples are shown. Passing-Bablok regression analysis gave a slope of 1.79 (1.47-
2.21), an intercept of 10.7 (8.4-12.3), and r = 0.491.
The HPLC method has been reported to provide earlier 
detection of diabetic nephropathy by a mean of 3.9 
years in type 1 diabetes mellitus and 2.4 years in type 2 
diabetes mellitus compared with a radioimmunoassay 
method for urinary albumin measurement using timed 
urine samples.7 Our data show that when using 
random urine samples from healthy subjects, the HPLC 
method yields albumin results that average nearly four 
times those of an ITA method and the upper reference 
limits for HPLC are double those of ITA.  Further 
studies are needed with random urine samples to 
confirm that the HPLC method can indeed predict 
which patients will go on to develop diabetic 
nephropathy earlier than conventional immunoassay 
methods for urinary albumin.  These studies should also 
determine method appropriate cutoff concentrations.
Conclusions
 The HPLC assay for urinary albumin studied shows 
good analytical performance.
 Further outcome studies are needed to evaluate how 
to best interpret urinary albumin results obtained by 
this HPLC method.
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Fig. 2.  HPLC versus ITA ACR method comparison.  The solid line indicates 
Passing-Bablok regression line and the dashed line indicates x = y.  In panel A, 
results from 101 samples with moderately elevated ACR (20-200 mg/g by ITA) 
are shown.  Passing-Bablok regression analysis gave a slope of 1.77 (1.57-2.03), 
an intercept of 2.2 (-10.4-11.1), and r = 0.828.  In panel B, results from 103 
samples with markedly elevated ACR (200 to 1000 mg/g by ITA) are shown. 
Passing-Bablok regression analysis gave a slope of 1.33 (1.21-1.47), an 
intercept of 20.0 (-27.8-65.8), and r = 0.870.
Fig. 1 Comparison of urinary albumin concentrations obtained by five 
methods using 100 patient samples.  The solid line indicates Passing-Bablok 
regression line and the dashed line indicates x = y.  In panel A, Passing-
Bablok regression analysis gave a slope of 1.06 (1.00 to 1.09), an intercept of   
-4.8 (-5.9 to -2.0), and r = 0.983.  In panel B, Passing-Bablok regression 
analysis gave a slope of 1.80 (1.66 to 2.02), an intercept of 2.4 (-2.0 to 10.4), 
and r = 0.912. In panel C, Passing-Bablok regression analysis gave a slope of 
1.13 (1.08 to 1.18), an intercept of -5.0 (-6.4 to -3.4), and r = 0.976.  In panel D, 
Passing-Bablok regression analysis gave a slope of 0.97 (0.94 to 1.00), an 
intercept of  -3.9 (-5.0 to -1.8), and r = 0.984.
Results and Discussion
The LOD was determined to be 3.4 mg/L, which is 
appropriate and comparable to the manufacturer’s 
claim of 3 mg/L.  The assay is was linear between 4.3 
and 240 mg/L with a maximum deviation from a mean 
recovery of 100% at 66 mg/L.  To verify that both 
HPLC and ITA assays were calibrated comparably, the 
linearity samples were also analyzed by ITA.  
Regression analysis of the HPLC versus ITA gave a 
slope of 0.91 with an intercept of 5.9 mg/L, indicating 
the two methods were calibrated comparably based on 
urine samples spiked with purified human serum 
albumin.  Imprecision data are summarized in Table 1.  
Total CV’s were less than 10% for all concentrations 
tested.  The lowest concentration tested was 15.9 mg/L 
and it showed the highest CV.  This indicates the assay 
has imprecision within published guidelines for MA 
testing.  Passing-Bablok analysis comparing albumin 
concentrations measured by ITA, HPLC, two INA 
methods and ICMA for patient samples with 
moderately elevated albumin excretion rates are shown 
in (Fig. 1). There was a positive proportional bias for 
HPLC compared to all of the immunoassay methods 
while all four immunoassay methods showed good 
agreement. This suggests that immunoassay 
harmonization may have improved since earlier 
reports.6,9 Passing-Bablok analysis comparing ACR by 
HPLC versus ITA for patient samples with moderately 
(Fig. 2A) and highly elevated (Fig. 2B) albumin 
excretion rates are shown. The overall correlations 
between ITA and HPLC (r = 0.83 and r = 0.87) were not 
as good as one might predict based on the relatively low 
imprecision of the two methods.  HPLC shows a positive 
proportional bias compared to ITA for both patient 
types, but the disparity decreases when the amount of 
albuminuria increases. It has been proposed that for 
diabetic patients, immunoassay based methods 
considerably underestimate urinary albumin excretion, 
particularly for rates less than 100 µg/min. This has 
been attributed to the presence of an intact form of 
albumin that is immuno-unreactive but detectable by 
HPLC.5 A summary of the non-parametric reference 
interval data for first or second morning void 
collections for adults and random collections for 
children is provided in the Table 2.  The 90% 
confidence intervals for upper reference limits are also 
shown.  These limits are generally quite broad even 
though there were more than 120 subjects in each 
group.  It is noteworthy that 80% of boys, 83% of girls, 
8% of men and 30% of women had an ACR by HPLC 
that was >30 mg albumin/g creatinine.  When men and 
women were combined, 14% had an ACR by HPLC 
>30 mg/g. In addition to determining urinary 
microalbumin reference intervals for the HPLC and 
ITA methods in units of mg/g creatinine, we also 
determined reference intervals in units of mg/L     
(Table 2).  It is noteworthy that when one compares 
adult male and female reference intervals using units of 
mg/L, the differences seen for the ACR disappear.  
Passing-Bablok analyses of comparisons between HPLC 
and ITA for the four reference groups are shown     
(Fig. 3).  All groups show similar slopes indicating 
positive proportional bias for HPLC relative to ITA.  
The curves also illustrate the higher ranges for females 
vs. males for pediatric and adults subjects, and the 
approximately 2 to 1 ratio for HPLC vs. ITA at the 
upper reference limit. It is interesting that we see 
substantial amounts of immuno-unreactive albumin in 
our apparently healthy reference subjects. In adults the 
higher results by HPLC, which presumably correspond 
to immuno-unreactive albumin, might be partially 
attributable to undiagnosed underlying chronic 
conditions such as hypertension, type 2 diabetes 
mellitus, metabolic syndrome, and cardiovascular risk.  
However, in children this explanation seems less likely.
included 20 male and 20 female subjects for each year of life 
from 7 to 17 for a total of 440 samples. All studies using samples 
from human subjects were approved by the Institutional Review 
Board of the University of Utah Health Sciences Center (Salt 
Lake City, UT). Linear regression and the general F-test for 
significance were performed using CBstat software version 5.0.0 
(Kristian Linnet, Risskov, Denmark).   EP Evaluator Release 5 
software (D.G. Rhoads Associates Inc., Kennett Square, PA) was 
used for evaluation of linearity, imprecision, Passing-Bablok 
regression, calculation of r, and reference interval estimation 
including Z-test for partitioning by age and gender.  Slope and 
intercept statistics for Passing-Bablok analysis are given as 
median with the 95% confidence interval in parentheses.  
Reference intervals were determined non-parametrically after 
exclusion of outliers as outlined in the NCCLS C28-A document.
